Biopharmx Corp., of Menlo Park, Calif., closed a registered direct offering following its entry into securities purchase agreements with certain existing institutional investors for the purchase and sale of about 6.4 million shares of common stock at a price of 78 cents per share with 50 percent warrant coverage (representing warrants to purchase up to about 3.2 million shares of common stock).